Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy.
ME/CFS
clinical trial
fatigue
oxygen-ozone therapy
ozone
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Dec 2021
22 Dec 2021
Historique:
received:
02
11
2021
revised:
29
11
2021
accepted:
01
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
(1) Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic syndrome characterized by fatigue as its major and most outstanding symptom. Previous evidence has supported the ability of ozone to relief ME/CFS related fatigue in affected patients (2) Methods: A number of 200 ME/CFS previously diagnosed patients, (mean age 33 ± 13 SD years) were consecutively treated with oxygen-ozone autohemotherapy (O
Identifiants
pubmed: 35011770
pii: jcm11010029
doi: 10.3390/jcm11010029
pmc: PMC8745272
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int Immunopharmacol. 2021 Jul;96:107777
pubmed: 34020394
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34400495
Mayo Clin Proc. 2012 Dec;87(12):1145-52
pubmed: 23140977
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2013 Sep;31(9):693-6
pubmed: 24064130
Am Fam Physician. 2002 Mar 15;65(6):1083-90
pubmed: 11925084
J Biol Chem. 2005 Dec 23;280(51):41921-7
pubmed: 16219762
Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5871-5875
pubmed: 34604980
Arch Intern Med. 2004 Nov 8;164(20):2241-5
pubmed: 15534161
BMJ. 2007 Sep 1;335(7617):446-8
pubmed: 17762037
Biomarkers. 2005 Nov;10 Suppl 1:S10-23
pubmed: 16298907
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
Oncoimmunology. 2015 May 27;4(9):e1027471
pubmed: 26405597
Anesth Pain Med. 2021 Jun 26;11(3):e113629
pubmed: 34540633
Arch Intern Med. 1993 Jan 11;153(1):116-7, 120
pubmed: 8422193
Pain Med. 2021 Oct 20;:
pubmed: 34668532
Psychother Psychosom. 2012;81(5):286-95
pubmed: 22832503
Brain Behav Immun. 2010 Oct;24(7):1209-17
pubmed: 20447453
BMC Fam Pract. 2010 Feb 23;11:16
pubmed: 20178588
Ann Oncol. 2004 Oct;15(10):1576
pubmed: 15367422
Brain Nerve. 2018 Jan;70(1):11-18
pubmed: 29348370
Scand J Immunol. 1994 Dec;40(6):601-8
pubmed: 7997849
J Transl Med. 2020 Feb 24;18(1):100
pubmed: 32093722
Mol Neurobiol. 2020 Nov;57(11):4598-4607
pubmed: 32761353
Int J Immunopathol Pharmacol. 2015 Mar;28(1):53-9
pubmed: 25816406
Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2847-52
pubmed: 24254550
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Dec 20;103:109976
pubmed: 32470498
Am J Med. 1998 Sep 28;105(3A):54S-58S
pubmed: 9790483
Int Immunol. 2014 Apr;26(4):233-42
pubmed: 24343819
J Clin Med. 2021 Oct 19;10(20):
pubmed: 34682909
Am Fam Physician. 2003 Jan 15;67(2):252; author reply 252
pubmed: 12562147
J Nat Sci Biol Med. 2011 Jan;2(1):66-70
pubmed: 22470237
Int J Mol Sci. 2021 Jul 23;22(15):
pubmed: 34360655
Ann Ist Super Sanita. 1999;35(3):435-41
pubmed: 10721210
J Clin Med. 2021 Jul 21;10(15):
pubmed: 34361987
In Vivo. 2010 Nov-Dec;24(6):865-9
pubmed: 21164046
Scand J Med Sci Sports. 2010 Apr;20(2):282-90
pubmed: 19422646
Medicina (Kaunas). 2021 Mar 23;57(3):
pubmed: 33806902
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7150-E7158
pubmed: 28760971
J Clin Med. 2020 May 21;9(5):
pubmed: 32455633
Integr Med Res. 2019 Jun;8(2):89-91
pubmed: 31193269
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8030-8033
pubmed: 30536352
Sci Rep. 2016 Jan 07;6:18680
pubmed: 26739627
J Affect Disord. 2012 Feb;136(3):933-9
pubmed: 21975140
Ann Epidemiol. 2004 Feb;14(2):95-100
pubmed: 15018881